Clinical Trials

Pfizer’s Zavicefta matches standard-of-care in treating hospital-acquired pneumonia in phase 3 study

Results from the phase 3 REPROVE study assessing Pfizer's fixed-dose antibacterial combo Zavicefta (ceftazidime-avibactam) in patients with hospital-acquired pneumonia (HAP) demonstrated a comparable cure rate to carbapenem antibiotic therapy, considered the standard of care.

NGM Bio’s NGM282 succeeds in nonalcoholic steatohepatitis phase 2 trial

NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients.

Ultragenyx’s hypophosphatemia drug succeeds in phase 3 study

Ultragenyx Pharmaceutical, Kyowa Hakko Kirin and Kyowa Kirin International have reported positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 trial of burosumab (KRN23) in X-linked hypophosphatemia (XLH) adult patients.

Relypsa’s Veltassa shows consistent efficacy in phase 4 trial to treat hyperkalemia

Relypsa’s Veltassa (patiromer) has demonstrated consistent effficacy and safety in phase 4 Tourmaline study in patients with hyperkalemia.

Mateon’s phase 2/3 trial in platinum-resistant ovarian cancer yields positive results

Mateon Therapeutics has revealed encouraging data from its first interim scheduled analysis of the ongoing phase 2/3 trial (FOCUS) in platinum resistant ovarian cancer (prOC) patients.

OncoMed’s demcizumab fails to meet primary endpoint in pancreatic cancer trial

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in previously untreated metastatic pancreatic cancer patients.

Medivir’s CTCL drug remetinostat yields positive data in phase II study

Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell Lymphoma patients.

Burosumab’s pediatric phase 2 studies in X-linked hypophosphatemia yield positive results

Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.

Allergan to advance Botox trial to third phase for treatment of depression

Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in treating patients with major depressive disorder (MDD).